

**Total Direct and Indirect Economic Output of the Biopharmaceutical Sector**

$78.8 billion

**Total Employment Supported by the Biopharmaceutical Sector**

285,273

A majority of Americans agree that even if it brings no immediate benefits, basic scientific research that advances the frontiers of knowledge is necessary and should be supported by the federal government.

Pennsylvanians with a rare disease

1 in 10

Total NIH Award Funding (FY17)

$1,676 million

---

**Research in the Keystone State**

*Children’s Hospital of Philadelphia, Philadelphia, PA*

The Children’s Hospital of Philadelphia’s (CHOP) Spark Therapeutics’ innovative gene therapy is an FDA approved treatment for a rare form of blindness. Known as LUXTERNA, this therapy is used to treat patients with a wide range of eye conditions that involve reduced or deteriorating vision in both eyes.

*ECOG-ACRIN Cancer Research Group, Philadelphia, PA*

The ECOG-ACRIN Cancer Research Group is conducting a clinical trial to determine the best ways to screen for breast cancer in women without symptoms. The trial, funded by the National Cancer Institute, will create a comparison between two FDA approved types of digital mammography: the standard digital 2-D and the newer 3-D mammography.

*University of Pittsburgh (Pitt), Harvard University, Boston’s Children Hospital, Pittsburgh, PA*

In collaboration with Harvard and Boston’s Children Hospital, Pitt researchers are developing new, more detailed electronic medical records (EMRs) for cancer patients. The additional data in these records, when de-identified, can provide a rich new resource for childhood cancer research.

---

*Sources: National Institutes of Health (NIH), Pharmaceutical Research and Manufacturers of America (PhRMA), Centers for Disease Control and Prevention (CDC), A Research America Survey of U.S. Adults Conducted in Partnership with Zogby Analytics in January 2017, Agency for Healthcare Quality and Research (AHRQ), CHOP, ECOG-ACRIN, ClinicalTrials.gov.*